March 8, 2017- Xarelto Pushed By Drug Companies For Heart Attack Prevention Despite Lawsuits
Bayer Healthcare and Janssen Pharmaceuticals reported on February 8 that Phase 3 Compass clinical trials for Xarelto were stopped early because it showed great success. The trials were meant to determine if the drug could be used to prevent cardiac events in patients. The companies are currently faced with thousands of lawsuits regarding the severe bleeding side effects connected to Xarelto. Despite these suits, they indicated in a statement that they would be looking to obtain FDA approval for the anticoagulant to be promoted as a heart attack prevention drug.
February 7, 2017 – New Lawsuit Alleging Death From Drug Side Effects Joins Xarelto MDL
Another lawsuit regarding Xarelto has joined MDL 2592. The children of a deceased woman have filed suit alleging that the manufacturers failed to warn consumers, medical professionals, and the FDA of the serious, life-threatening side effects associated with the drug. In particular, these plaintiffs reference the negligence of the companies to release the anticoagulant without an antidote to reverse the effects of the drug in the case of emergency bleeding. The plaintiffs, in this case, allege that as a result of Xarelto, their mother suffered life-threatening bleeding, anemia, sepsis and kidney failure before she passed away in January of 2016. The first of the four bellwether trials for MDL 2592 is scheduled to begin in March of this year.
January 24, 2017 – Study Finds Xarelto To Be Least Favorable Among New Blood Thinners
A new study was published on December 31, 2016, in the medical journal Gastroenterology in which Mayo Clinic researchers compared the safety profiles of Xarelto, Eliquis, and Pradaxa. All of the anticoagulants looked at are fairly new and have been developed as replacements to the traditional warfarin. All three drugs have had reports of uncontrollable bleeding and complications as well as thousands of lawsuits claiming injury or wrongful death. Researchers found in the population-based study that Xarelto had higher bleeding rates than the other two anticoagulants studied and it was the least favorable. Drugmakers are still seeking a reversal agent for Xarelto which would make it much safer.
December 2, 2016 – Woman’s Suit Added To Xarelto Litigation
A woman filed a complaint on November 14 against numerous defendants, including Bayer AG, in Cook County Circuit Court. The plaintiff alleges that due to her use of the anticoagulant, Xarelto, she suffered severe physical injuries. Her complaint also alleges that the defendants who manufacture and distribute the drug were responsible for her injuries because they failed to warn consumers of the possible side effects of the drug. The plaintiff seeks compensation greater than $50,000.
November 7, 2016 – Bellwether Selection Process Determined For Philadelphia Xarelto Mass Tort Program
The Philadelphia mass tort program consists of about 1,000 pending Xarelto lawsuits which are similar to the over 7,000 Xarelto lawsuits consolidated in an MDL in the Eastern District of Louisiana. A judge recently ruled how bellwether cases will be selected for trial. Selection of bellwether trial cases will begin in the summer of 2017 and a total of 24 cases will be selected. Trials are scheduled to begin in September and December of 2017. Bellwether cases for the Louisiana MDL have already been selected and are scheduled to begin in early 2017.
October 6, 2016 – Higher Bleeding Risk Found With Xarelto When Compared To Pradaxa
According to study findings published in the journal JAMA Internal Medicine, Xarelto has a “slight increased risk of bleeding” in comparison to Pradaxa in patients with atrial fibrillation. For the study which was conducted at the FDA’s Center for Drug Evaluation and Research, data was collected on close to 119, 000 Medicare patients with atrial fibrillation treated with either Xarelto or Pradaxa. Little difference was found in stroke risk but a statistically significant increase of stomach and brain bleeding was found in patients taking Xarelto.
September 19, 2016 – Judge Fallon Extends Deadline To File Xarelto Lawsuits Another 90 Days
In mid-August, weeks after the bellwether cases were selected for trial in the MDL, a deadline extension of 90 days was allowed for some plaintiffs to file Xarelto lawsuits. Judge Fallon explained that the extension was made due to the high influx of complaints seen by the clerk’s office. The first bellwether trial is scheduled to occur in February and there are currently over 7,000 lawsuits consolidated in the MDL. Meanwhile, in Philadelphia, the first trials in the mass tort program are expected to begin next year, in August, as a bellwether program is being negotiated.
August 19, 2016 – Trials For Xarelto Litigation Have Been Selected And Scheduled
Judge Eldon Fallon, who is overseeing the Xarelto MDL 2592, has indicated that four cases will be going to trial starting in February of next year. These four cases are part of the bellwether trials selected in order to streamline the litigation which is now comprised of over 6,400 lawsuits. The first trial will include plaintiffs who originally filed in Louisiana and suffered a bleeding event while between the ages of 50 to 90 years old. The second trial will have plaintiffs who suffered a brain bleed, a stroke, or an injury that resulted in death. The third trial will include plaintiffs who filed in Mississippi originally, suffered gastrointestinal bleeding, and were between the ages of 40 to 80 years old when the event occurred. The fourth trial will take place in Texas involving a bleeding event.
April 14, 2016- Xarelto Litigation Plaintiffs Band Together To Jointly File A Lawsuit
A group of 10 Xarelto litigation plaintiffs from various states have banded together to jointly file a lawsuit. The reason they are doing this is due to the resemblances in their allegations towards the adverse results, mainly death, suffered from using Xarelto. Those filing this litigation are groups of family members who represent deceased loved ones, who died due to serious medical complications they had while using Xarelto. The lawsuits were jointly filed on November 20, 2015.
March 16, 2016- Xarelto Bellwether Cases Due To Be Chosen
A total of 40 cases are set to be chosen for the Xarelto bellwether pool, this is by order issued by U.S. District Judge Eldon Fallon. Selection of the cases will be made with each side choosing 10 cases and a further 20 cases that will be selected randomly. In December 2014, Xarelto lawsuits were combined into a multi-district litigation (MDL).